| Property | Value |
|---|---|
| Gene Symbol | TFR1 |
| Full Name | Transferrin Receptor 1 |
| Chromosomal Location | 3q29 |
| NCBI Gene ID | 7037 |
| Ensembl ID | ENSG00000149571 |
| Encoded Protein | TfR1 (CD71) |
| Protein Class | Type II transmembrane glycoprotein |
| Expression | Ubiquitous, highest in proliferating cells and erythroid precursors |
The TFR1 (Transferrin Receptor 1) gene encodes a type II transmembrane glycoprotein that serves as the primary cellular entry point for iron bound to transferrin.[1] TFR1 is essential for cellular iron uptake and is ubiquitously expressed, with highest levels in proliferating cells, erythroid precursors, and certain neuronal populations.[2] In the central nervous system, TFR1-mediated iron uptake plays a critical role in maintaining iron homeostasis—a process that becomes dysregulated in multiple neurodegenerative diseases.[3]
Unlike most cellular receptors, TFR1 undergoes regulated internalization via clathrin-mediated endocytosis, making it a key node in the Iron Dysregulation mechanism central to neurodegeneration.[4] The receptor's structure consists of an extracellular transferrin-binding domain, a single transmembrane helix, and a cytoplasmic tail that mediates endocytosis and recycling.[1:1]
TFR1 binds iron-loaded transferrin (Fe-Tf) with high affinity (Kd ≈ 10⁻⁹ M) and internalizes the iron-transferrin complex through clathrin-coated pits.[1:2] Within endosomes, the acidic pH promotes iron release from transferrin, while the apotransferrin-TFR1 complex recycles back to the cell surface where apotransferrin dissociates.[2:1] This efficient recycling mechanism allows cells to acquire iron without degrading the receptor or its ligand.
The process can be summarized as:
TFR1 expression is tightly regulated at multiple levels:
The brain requires precise iron regulation because both iron deficiency and iron excess are neurotoxic. Neurons obtain iron primarily through TFR1-mediated uptake of transferrin-bound iron from the cerebrospinal fluid (CSF) and interstitial fluid.[3:1] Unlike other cell types, neurons also express additional iron transporters including DMT1 and ZIP8, creating redundancy in iron acquisition pathways.[7]
Key aspects of neuronal iron handling include:
Iron is essential for numerous neuronal processes:
Parkinson's disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). This region has the highest iron concentration in the brain, making iron homeostasis particularly relevant to PD pathogenesis.[9]
Evidence for TFR1 involvement in PD:
Mechanistic links:
Alzheimer's disease (AD) involves progressive memory loss and cognitive decline due to amyloid-β plaque accumulation and tau neurofibrillary tangles. Iron dysregulation is increasingly recognized as a contributor to AD pathogenesis.[13]
Evidence for TFR1 involvement in AD:
Mechanistic links:
Amyotrophic Lateral Sclerosis (ALS):
Restless Legs Syndrome (RLS):
Friedreich's Ataxia:
TFR1 presents both opportunities and challenges as a therapeutic target:
Targeting strategies:
Challenges:
TFR1's capacity for receptor-mediated transcytosis makes it valuable for CNS drug delivery:
Several TFR1 polymorphisms have been studied in neurodegenerative contexts:
While primarily studied in neurodegeneration, TFR1 also plays roles in neurodevelopment:
Key experimental approaches include:
TFR1 has been explored as a biomarker:
Trowbridge IS, et al. Structure and function of the human transferrin receptor. Annu Rev Nutr. 1993. ↩︎ ↩︎ ↩︎
Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol. 1999. ↩︎ ↩︎
Moos T, et al. Cellular distribution of iron in the normal rat brain and in models of iron deficiency and iron overload. J Neurosci Res. 2000. ↩︎ ↩︎
Richardson DR, et al. More than just iron: new concepts in cellular iron homeostasis. Nat Rev Gastroenterol Hepatol. 2015. ↩︎
Hentze MW, et al. Ferritin and iron: the ferritin iron responsive element. Cell. 2004. ↩︎
Tacchini L, et al. Transferrin receptor induction by hypoxia. J Biol Chem. 1996. ↩︎
Connor JR, et al. Neuronal iron homeostasis. Neurology. 2002. ↩︎
Connor JR, et al. Cellular distribution of ferritin subunits in the human brain. Brain Res. 1990. ↩︎
Dexter DT, et al. Increased iron in the substantia nigra of patients with Parkinson's disease. J Neurochem. 1989. ↩︎ ↩︎
Oakley AE, et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology. 2007. ↩︎
Borie C, et al. Association between the C2G>A polymorphism of the transferrin receptor gene and Parkinson's disease. Eur J Neurol. 2002. ↩︎ ↩︎
Faucheux BA, et al. Transferrin receptors in human mesencephalic dopaminergic neurons. Neuroscience. 1999. ↩︎
Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci. 2003. ↩︎ ↩︎
Pinero DJ, et al. Iron in the brain: an important contributor to normal neuronal function. Bioessays. 2000. ↩︎
Rogers JT, et al. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem. 2002. ↩︎
Jeong SY, et al. Iron in the motor neuron disease: a review. Free Radic Biol Med. 2009. ↩︎
Connor JR, et al. Brain iron homeostasis: from bench to bedside. Neurology. 2012. ↩︎
Puccio H, et al. Mouse models for Friedreich's ataxia. Biochim Biophys Acta. 2001. ↩︎
Khincha PP, et al. Iron chelation therapy in neurodegenerative disease. Mol Neurobiol. 2016. ↩︎
Bickel U, et al. vivo performance of a. The in liposomal delivery system for brain targeting. Pharm Res. 1993. ↩︎ ↩︎
Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier. Neurotherapeutics. 2015. ↩︎
Beard JL. Iron deficiency and neural development: an overview. Nutr Rev. 1995. ↩︎
Kuiper MA, et al. Cerebrospinal fluid transferrin in neurodegenerative disease. J Neurol Neurosurg Psychiatry. 1994. ↩︎